Evidence Repository
The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
Link to SEPIO compliant JSON-LD document
  • There was no gene found in the curated document received from the VCI/VCEP
  • Gene listed was thus derived from ClinVar and/or CAR
  • The variant label for this record ("m.8363G>A") does not appear to be in HGVS format

Variant: m.8363G>A

CA120555

9581 (ClinVar)

Gene: MT-TK
Condition: mitochondrial disease
Inheritance Mode: Mitochondrial inheritance
Link to MONDO
UUID: 44d7627d-c369-4639-a684-442ac13e2847

HGVS expressions

NC_012920.1:m.8363G>A
J01415.2:m.8363G>A

Likely Pathogenic

The Expert Panel has overridden the computationally generated classification - "Uncertain Significance - Insufficient Evidence"
Met criteria codes 5
PP3 PM2_Supporting PS4_Moderate PP1_Moderate PS3_Supporting
Not Met criteria codes 2
PM6 PS2

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Mitochondrial Disease Nuclear and Mitochondrial Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 1_mtDNA

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Mitochondrial Diseases VCEP
The m.8363G>A variant in MT-TK has been reported in at least 30 individuals with primary mitochondrial disease from 12 kindreds. Features seen in affected individuals include Leigh syndrome and myoclonic epilepsy with ragged red fibers (MERRF), as well as myopathy, peripheral neuropathy, ataxia, cardiomyopathy, sensorineural hearing loss, ophthalmoplegia, and lipomas. Heteroplasmy levels of this variant in affected individuals is variable, ranging from 40-97% (PS4_moderate; PMIDs: 8651277, 9052804, 10868777, 11108511, 19278689, 18319067, 19370763, 10102446, 16326995, 9932960). This variant segregated with disease in multiple affected family members in multiple families and several healthy family members had lower to undetectable levels (PP1_moderate; PMIDs: 9052804, 10868777, 10102446, 9932960). There are no confirmed de novo occurrences of this variant to our knowledge. The computational predictor MitoTIP suggests this variant impacts the function of this tRNA with a score of 94.3 percentile, as does HmtVar with a score of 0.75 (PP3). This variant is absent in the GenBank dataset, Helix dataset, and gnomAD v3.1.2 (PM2_supporting). Single fiber testing and cybrid analysis further support the functional impact of this variant (PS3_suporting). Single fiber testing showed the variant was significantly higher in COX-negative ragged red fibers (n = 5; 97.3% ± 2.5) than in normal fibers (n = 5; 89.2 ± 8.3; p < 0.05; PMID: 9932960). Cybrid studies showed that clones with the variant present at homoplasmy had statistically significant decreases in Complex I, ATP synthase, and oxygen consumption (PMIDs: 15554876, 25909222). In summary, this variant meets criteria to be classified as likely pathogenic for primary mitochondrial disease inherited in a mitochondrial manner. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Variant Curation Expert Panel on March 13, 2023. Mitochondrial DNA-specific ACMG/AMP criteria applied (PMID: 32906214): PS4_moderate, PP3, PP1_moderate, PS3_supporting, PM2_supporting.
Met criteria codes
PP3
The computational predictor MitoTIP suggests this variant impacts the function of this tRNA with a score of 94.3 percentile, as does HmtVar with a score of 0.75 (PP3).
PM2_Supporting
This variant is absent in the GenBank dataset, Helix dataset, and gnomAD v3.1.2 (PM2_supporting).
PS4_Moderate
The m.8363G>A variant in MT-TK has been reported in at least 30 individuals with primary mitochondrial disease from 12 kindreds. Features seen in affected individuals include Leigh syndrome and myoclonic epilepsy with ragged red fibers (MERRF), as well as myopathy, peripheral neuropathy, ataxia, cardiomyopathy, sensorineural hearing loss, ophthalmoplegia, and lipomas. Heteroplasmy levels of this variant in affected individuals is variable, ranging from 40-97% (PS4_moderate; PMIDs: 8651277, 9052804, 10868777, 11108511, 19278689, 18319067, 19370763, 10102446, 16326995, 9932960).
PP1_Moderate
This variant segregated with disease in multiple affected family members in multiple families and several healthy family members had lower to undetectable levels (PP1_moderate; PMIDs: 9052804, 10868777, 10102446, 9932960).
PS3_Supporting
Single fiber testing and cybrid analysis further support the functional impact of this variant (PS3_suporting). Single fiber testing showed the variant was significantly higher in COX-negative ragged red fibers (n = 5; 97.3% ± 2.5) than in normal fibers (n = 5; 89.2 ± 8.3; p < 0.05; PMID: 9932960). Cybrid studies showed that clones with the variant present at homoplasmy had statistically significant decreases in Complex I, ATP synthase, and oxygen consumption (PMIDs: 15554876, 25909222).
Not Met criteria codes
PM6
There are no confirmed de novo occurrences of this variant to our knowledge.
PS2
There are no confirmed de novo occurrences of this variant to our knowledge.
Approved on: 2023-03-13
Published on: 2023-03-17
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.